GlobeNewswire Inc | Jul 29, 2020 08:00AM EDT

July 29, 2020

EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time.

Conference Call DetailsWednesday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free: 866-269-4260International: 323-347-3612Conference ID: 8881331Webcast: http://public.viavid.com/index.php?id=141049

AboutZogenixZogenixis a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The companys first rare disease therapy, FINTEPLA(fenfluramine) oral solution, C-IV has been approved by theU.S.FDA and is under review inEuropefor the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. In addition, the company has two late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare childhood-onset epilepsy and one for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, aZogenixcompany.

CONTACTS:ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 | corpcomms@zogenix.com

Investors Brian RitchieManaging Director, LifeSci Advisors LLC+1 (212) 915-2578 | britchie@lifesciadvisors.com